EBV-specific T-Cell immunity in pediatric solid organ graft recipients with posttransplantation lymphoproliferative disease

Transplantation

Volumn 95, Issue 1, 2013, Pages 247-255

  Wilsdorf, Nadine ^a,b   Eiz Vesper, Britta ^a,b   Henke Gendo, Cornelia ^a   Diestelhorst, Jana ^a,g   Oschlies, Ilske ^c   Hussein, Kais ^a   Pape, Lars ^a,b   Baumann, Ulrich ^a,b   Tönshoff, Burkhard ^d   Pohl, Martin ^e   Höcker, Britta ^d   Wingen, Anne Margret ^f   Klapper, Wolfram ^c   Kreipe, Hans ^a   Schulz, Thomas F ^a   Klein, Christoph ^a,g   Maecker Kolhoff, Britta ^a,b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Integrated Research and Treatment Center Transplantation   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e UNIVERSITY OF FREIBURG   (Germany)

^f UNIVERSITY OF DUISBURG ESSEN   (Germany)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; GAMMA INTERFERON; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE; VIRUS ANTIGEN;

ADOLESCENT; ARTICLE; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS PRESENTATION; DRUG RESPONSE; EPSTEIN BARR VIRUS; FEMALE; FLOW CYTOMETRY; GRAFT RECIPIENT; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENCE; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LYMPHOBLASTOID CELL LINE; LYMPHOPROLIFERATIVE DISEASE; MALE; ORGAN TRANSPLANTATION; PEDIATRICS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; T LYMPHOCYTE; VIRUS LOAD; VIRUS REACTIVATION;

ADOLESCENT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CHILD; CHILD, PRESCHOOL; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; INFANT; LYMPHOPROLIFERATIVE DISORDERS; MALE; ORGAN TRANSPLANTATION; T-LYMPHOCYTES;

EID: 84872068149     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318279968d     Document Type: Article

References (18)

1. Savoldo B, Rooney CM, Quiros-Tejeira RE, et al. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant 2005; 5: 566.
2. Cohen JI, Bollard CM, Khanna R, et al. Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas. Leuk Lymphoma 2008; 49: 27.
3. Smets F, Latinne D, Bazin H, et al. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 2002; 73: 1603.
4. Sebelin-Wulf K, Nguyen TD, Oertel S, et al. Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with pltd. Transpl Immunol 2007; 17: 203.
5. Long HM, Taylor GS, Rickinson AB. Immune defence against EBV and EBV-associated disease. Curr Opin Immunol 2011; 23: 258.
6. Jagadeesh D, Woda BA, Draper J, et al. Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations. Curr Treat Options Oncol 2012; 13: 122.
7. Gross TG, Orjuela MA, Perkins SL, et al. Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group report. Am J Transplant 2012; 12: 3069.
8. Guppy AE, Rawlings E, Madrigal JA, et al. A quantitative assay for Epstein-Barr virus-specific immunity shows interferon-gamma producing CD8+ T cells increase during immunosuppression reduction to treat posttransplant lymphoproliferative disease. Transplantation 2007; 84: 1534.
9. Nehring AK, Dua U, Mollee P, et al. Epstein-Barr virus T-cell immunity despite rituximab. Br J Haematol 2007; 136: 628.
10. Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBVspecific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010; 115: 925.
11. Khanna R, Tellam J, Duraiswamy J, et al. Immunotherapeutic strategies for EBV-associated malignancies. Trends Mol Med 2001; 7: 270.
12. Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007; 110: 1123.
13. Moosmann A, Bigalke I, Tischer J, et al. Effective and long-term control of EBV PLTD after transfer of peptide-selected T cells. Blood 2010; 115: 2960.
14. Schober T, Framke T, Kreipe H, et al. Characteristics of early and late PTLD development in pediatric solid organ transplant recipients. Transplantation; 2013; 95: 240.
15. Ghobrial IM, Habermann TM, Macon WR, et al. Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases? Transplantation 2005; 79: 244.
16. Selenko N, Maidic O, Draxier S, et al. CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. Leukemia 2001; 15: 1619.
17. Schiffer L, Henke-Gendo C, Wilsdorf N, et al. CXCL13 as a novel marker for diagnosis and disease monitoring in pediatric PTLD. Am J Transplant 2012; 12: 1610.
18. Maecker B, Mougiakakos D, Zimmermann M, et al. Dendritic cell deficiencies in pediatric acute lymphoblastic leukemia patients. Leukemia 2006; 20: 645.